The present invention relates to a method for the industrial preparation of ((2S)-3-([1,1′-biphenyl]-4-yl)-2-((((R)-1-aminoethyl)(hydroxy)phosphoryl)methyl)propanoyl)-L-alanine acid of following formula (E):

##STR00001##

from (S)-1-phenylethylamine via a multi-step synthesis.

The present invention pertains to a method for the industrial preparation of the disodium salt of ((2S)-3-([1,1′-biphenyl]-4-yl)-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl)methyl)propanoyl)-L-alanine of following formula (I):

##STR00002##

in two additional steps from the compound (E) such as defined above.

The present invention also pertains to a method for diastereoisomeric enrichment of the intermediates of the method for the industrial preparation of the compound of formula (E) of the present invention.

A surface treatment agent including a compound represented by the general formula HO—P(═O)R.sup.1R.sup.2 in which R.sup.1 and R.sup.2 are each independently bonded to the phosphorus atom and are each independently a hydrogen atom, an alkyl group, a fluorinated alkyl group, or an aromatic hydrocarbon group which may have a substituent, provided that R.sup.1 and R.sup.2 are not hydrogen atoms at the same time, and an organic solvent.

The present disclosure relates to a novel crystalline form of L-glufosinate ammonium salt and a process for preparation thereof. The present disclosure also provides compositions comprising said form and a method for the control of undesired plant growth using said compositions.

The present disclosure relates to a novel crystalline form of L-glufosinate ammonium salt and a process for preparation thereof. The present disclosure also provides compositions comprising said form and a method for the control of undesired plant growth using said compositions.

The invention relates to a mixture of at least one dialkylphosphinic acid of the formula (I)

##STR00001##

in which R.sup.1, R.sup.2 are the same or different and are each C.sub.1-C.sub.18-alkyl, C.sub.2-C.sub.18-alkenyl, C.sub.6-C.sub.18-aryl, C.sub.7-C.sub.18-alkylaryl, with at least one different dialkylphosphinic acid of the formula (II)

##STR00002##

in which R.sup.3, R.sup.4 are the same or different and are each C.sub.1-C.sub.18-alkyl, C.sub.2-C.sub.18-alkenyl, C.sub.6-C.sub.18-aryl and/or C.sub.7-C.sub.18-alkylaryl, with the proviso that at least one of the R.sup.3 and R.sup.4 radicals is different than R.sup.1 and R.sup.2.

The invention relates to a mixture of at least one dialkylphosphinic acid of the formula (I)

##STR00001##

in which R.sup.1, R.sup.2 are the same or different and are each C.sub.1-C.sub.18-alkyl, C.sub.2-C.sub.18-alkenyl, C.sub.6-C.sub.18-aryl, C.sub.7-C.sub.18-alkylaryl, with at least one different dialkylphosphinic acid of the formula (II)

##STR00002##

in which R.sup.3, R.sup.4 are the same or different and are each C.sub.1-C.sub.18-alkyl, C.sub.2-C.sub.18-alkenyl, C.sub.6-C.sub.18-aryl and/or C.sub.7-C.sub.18-alkylaryl, with the proviso that at least one of the R.sup.3 and R.sup.4 radicals is different than R.sup.1 and R.sup.2.

The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.

The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.

Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate. In some embodiments, a portion of the glutamate in the starting composition may be separated from the L-glufosinate using a crystallization step. Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are also described.

The present invention relates to STAT3 degraders, their liquid formulations, and methods of use thereof for treating cancer.